Home / Transcripts / Cronos Group Inc. (CRON) · August 6, 2026

Cronos Group Inc. (CRON) Earnings Call Transcript

August 6, 2026

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 28 min

Earnings Call Speaker Segments

Operator operator
#1

Good morning, everyone. I'm Haley, and I'll be the conference operator for today. I'd like to welcome all of you to Cronos' conference call for the 2026 second quarter. This call is being recorded today. At this point, I'll hand things over to Harrison Aaron, Senior Director of Investor Relations and Corporate Development. Please go ahead.

Harrison Aaron executive
#2

Thanks, Haley. And thanks to everyone for being here today as we go through Cronos' financial and business results for the second quarter of 2026. With me on the call are Mike Gorenstein, our Chairman, President, and CEO, as well as Anna Shlimak, our CFO. This morning Cronos put out a news release with our financial results, and that release has been filed on our EDGAR and SEDAR profiles. You'll also find this information and the prepared remarks posted on our website in the Investor Relations section. Before handing things over to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Those forward-looking statements rest on management's current expectations and assumptions, and they carry risks and uncertainties that could make actual results differ materially from what those forward-looking statements project. You can find the factors that could cause actual results to differ materially from expectations detailed in our earnings materials and in our SEC filings, which are available on our website, and those filings qualify in their entirety any forward-looking statements we make during this call. Details on non-GAAP financial measures, including reconciliations to U.S. GAAP, are likewise in the earnings materials available on our website. Finally, throughout this conference call we will be making statements about market share information, and unless we state otherwise, all market share data comes from Hifyre.

Harrison Aaron executive
#3

Prepared remarks come first, and after that we'll open things up for questions and answers. So with that, I'll hand things over to Mike Gorenstein, Cronos' Chairman, President, and CEO.

Mike Gorenstein executive
#4

Thanks, Harrison. Cronos turned in an outstanding second quarter, with organic records set in net revenue, gross profit, and adjusted EBITDA, as our borderless product strategy keeps building momentum in every region where we operate. Yesterday, the Trade Levies Commissioner of the Israeli Ministry of Economy and Industry announced the launch of a fresh investigation into alleged dumping of medical cannabis imports from Canada. That announcement comes after the Commissioner's earlier investigation, which ended without any anti-dumping duty being imposed. We reject the allegations behind this investigation. We will cooperate fully with the Ministry and are confident the facts are on our side. Our stance remains the same: Cronos does not engage in dumping. During the prior investigation into these same allegations, we gave the Trade Commissioner thorough pricing and cost data showing that our prices in the Israeli market were not below our prices in Canada. We fully stand behind that evidence. In recent years, several geopolitical and regulatory issues have made operating in Israel uniquely difficult. Even so, we will remain committed to Cronos Israel, as we have been since 2017, when we obtained our medical cannabis license.

Mike Gorenstein executive
#5

We've established a solid infrastructure in Israel, putting more than 100 million New Israeli Shekels into a greenhouse, a manufacturing facility, and a cannabinoid R&D lab. Among cannabis manufacturers in Israel, we rank as one of the biggest, and our team numbers roughly 80 people. That group has shown tremendous resilience, turning in record results time and again even with the challenges just mentioned. This quarter followed the same pattern, as Cronos Israel posted its tenth straight quarter of record net revenue, up 60% year-over-year, which works out to 32% growth on a constant currency basis. According to pharmacy data Cronos collects, the Peace Naturals brand keeps widening its lead in the Israeli medical cannabis market. Lord Jones has now had its second quarter of sales in Israel, and the brand is picking up momentum in the premium flower segment. Moving to Canada, we posted record net revenue, and our brands drove 25% year-over-year retail sales growth, compared with industry-wide sales growth of 1% per Hifyre. Spinach had another outstanding quarter, and our product portfolio keeps showing how well our innovation efforts are paying off through meaningful share gains. In Canada, Spinach held the number one spot in vapes for a second quarter running, with total vape market share climbing to 10.6%.

Mike Gorenstein executive
#6

Looking at the vape cartridge segment in particular, Spinach held the top spot for a third quarter running, and its share grew to 11.8%. Over in disposable vapes, Spinach took the number two position during Q2, with share climbing to 8.2%, powered by our Puffers all-in-one innovation that debuted late in Q4 2025. During the second quarter we added three fresh Puffers flavors: Strawberry Burst, Peach Iced Tea, and Grape Gas. We also brought out the Spinach Orange Vanilla Twist 1-gram cartridge — the brand's first limited-time vape cartridge offer for the summer season. Turning to edibles, Spinach stayed Canada's top brand for an eighth quarter in a row, holding market share flat at 20.8% and reaching 22.5% share within gummies. In Q2, five of the ten best-selling edible SKUs in Canada were SOURZ by Spinach fully blasted offerings, among them the country's number one edible, the fully blasted Blue Raspberry Watermelon 10-pack. On the flower side, Spinach came in at number three in Canada, with market share growing to 5.4%. Two Spinach flower strains — GMO Cookies and OG Kush — ranked among the six top-selling flower products nationwide for the quarter. In pre-rolls, Spinach moved up to number seven in Canada, with market share rising to 3.1%. And within infused pre-rolls, Spinach advanced to number six, with market share increasing to 3.5%.

Mike Gorenstein executive
#7

When it comes to traditional pre-rolls, Spinach also climbed to sixth place, and its market share grew to 2.9%. During this quarter, Spinach Sticks — the first cylindrical-style pre-roll from the brand — became available more broadly in additional Canadian provinces. Shifting to our other international markets beyond Israel, we posted record net revenue, up 88% compared with a year earlier, driven by robust demand in Germany. Our international footprint's breadth keeps delivering meaningful growth as we carry out a borderless product strategy. Continuing that international momentum, this week I had the chance to meet with the CanAdelaar team in the Netherlands, and that business is performing as we expected. Once we receive regulatory clearance in the Netherlands and the remaining closing conditions are satisfied or waived, we are ready to complete the CanAdelaar acquisition. We anticipate closing the acquisition in the second half of 2026. No specific issues with our regulatory clearance submission have been communicated to us, and although closing has taken longer than we would have liked, judging from the information we have, the timeline seems consistent with the normal course of the Dutch regulatory review process for a transaction of this kind. As a reminder, CanAdelaar is the biggest company operating in the Netherlands' legal adult-use cannabis program.

Mike Gorenstein executive
#8

We can't wait for CanAdelaar to become part of the Cronos family. Our capital allocation priorities keep moving forward, and we're still active under the share repurchase program, which we see as an appealing way to deploy capital. With an industry-leading balance sheet behind us and positive cash flow from operations, we're well positioned to put money into our growth strategy, return capital to shareholders, and keep the flexibility to act opportunistically when appealing opportunities come up. At this point, I'll hand things over to Anna, who will take you through the second quarter financials.

Anna Shlimak executive
#9

Thanks, Mike, and good morning to everyone. I'll walk you through the results for our second quarter of 2026. Consolidated net revenue came in at $53 million for the company, which is up 58% compared with the same period a year ago. That growth in net revenue was mainly fueled by stronger sales of cannabis flower in Israel, Canada, and other countries — Germany in particular — along with greater sales of cannabis extracts in the Canadian market. Gross profit for the second quarter reached $28.5 million, which works out to 96% growth over the gross profit we posted in Q2 2025. That year-over-year gain came largely from higher average selling prices — mostly the result of a mix shift toward Israel and other countries, where no excise taxes apply — as well as from larger sales volumes. Those higher volumes drove both greater net revenue and efficiencies gained through overhead cost absorption. The gross margin this quarter shows what our business can look like when everything is firing on all cylinders, and Q2 also got a boost from seasonally better growing conditions. That said, gross margins can fluctuate from one quarter to the next because of things like seasonality, product and geographic mix, production volumes, and possible price compression. For that reason, we think looking at our gross margin performance across a trailing 12-month period gives more useful context than any single quarter does. Total operating expenses for the quarter were $21 million, which is $1.2 million higher than a year ago, driven by upticks in sales and marketing, R&D, and G&A expenses.

Anna Shlimak executive
#10

Keep in mind that $500,000 of that $1.2 million rise in opex versus a year ago came from transaction costs, mainly tied to our pending purchase of CanAdelaar. Second-quarter adjusted EBITDA reached a record $13.1 million, up $11.4 million from the prior year, as greater gross profit drove the gain and higher operating expenses partly offset it. Moving to the balance sheet and cash flow statement, we finished the quarter holding $827 million across cash, cash equivalents, short-term investments, and non-current interest-bearing deposits, which is $5 million above Q1 2026, mainly because operations generated $24 million of positive cash flow, partly offset by $16 million used for share repurchases and $2 million spent on capex. Beyond that $827 million, we also carry a $17 million loan receivable, a $15 million current income tax receivable, and $5 million in other investments. To sum up, 2Q brought record net revenue, gross profit, and adjusted EBITDA, which reflects our focused strategy, the momentum underlying our business, and the team's continued strong execution. With that, we'll now open the call for questions.

Operator operator
#11

Thanks. We’ll begin the question-and-answer portion now. If you’d like to ask something, dial *11 on your phone. If you want to take your question back, dial *11 once more. Please hold while we put the Q&A list together. First up is Bill Kirk with ROTH Capital Partners. Your line is open.

Bill Kirk analyst
#12

Morning, everyone — thanks for having me. I'd like to raise a question about Spinach. That brand's strength has been evident, and it has enabled the brand to move beyond individual product formats. Could you share how you see the brand going forward and what potential it has to perhaps move into other countries and go beyond national boundaries, where at some point an adult-use brand could make sense?

Mike Gorenstein executive
#13

Appreciate that — it's a really good question. I'd say one reason Spinach has performed well across various categories is that we've never simply relied on the brand's existing reputation. We treat every category separately, approaching each product as though it were a brand-new launch and ensuring it ranks among the best available. In each and every market, you still have to earn consumers over. If we keep taking that same approach, I believe we'll manage to do so. I think we've already demonstrated that our products can carry over into other markets. That's definitely something we intend to do, and it's among the reasons the CanAdelaar acquisition has us so enthusiastic. That's an adult-use market where we believe Spinach will have a strong chance to succeed and to see products such as SOURZ and Puffers carry over. Then,

Bill Kirk analyst
#14

Turning to Germany, if I may. Conditions have become somewhat more difficult there for certain players due to some price compression, yet you're posting robust growth in that country. Could you help us get a handle on perhaps how you reach the market in Germany? Did the unlocking of Germany, your getting larger there, really stem from the extra capacity at GrowCo, and are you only now meeting demand that already existed there? Could you speak to the German market, how your product makes its way into Germany, and how you are positioned in that country?

Mike Gorenstein executive
#15

Sure. What we're succeeding on really isn't all that different from Canada or Israel, where you can also look at the data and see it's competitive and tough. I think it ultimately comes down to having the right value proposition for patients or consumers. Even though we don't have people on the ground the way we do in Canada and Israel, ultimately, if the product is great, I think demand finds a way. We get the backdrop and the competitiveness. From where I sit, it's actually not as competitive yet as some other markets we're in. I think that's the unlock. We aren't really avoiding competition. We want to make sure we win in whatever market we're in. I think having the discipline to keep adapting and making sure you win kind of sharpens and improves the offering you have. Now that we have additional capacity, there's much more focus on Europe than there was previously.

Bill Kirk analyst
#16

Thanks, Mike. Anna, may I finish with a question about gross margin? It came in higher than we had anticipated, which clearly is a positive. You split it into a few buckets, and those included average selling price and mix. Could you perhaps tell us which of those buckets contributed the most to the gross margin expansion year over year? Sure,

Anna Shlimak executive
#17

Glad to give a little additional detail on that. As I mentioned, seasonally improved growing conditions worked in our favor, and that shows up in two ways: bigger yields and a larger amount of top-quality grade A flower available for sale. Naturally, having more flower helps with efficiencies, since our fixed overhead gets distributed across larger volumes. That, I would say, is likely the biggest driver. On top of that, you've got the geographic move toward higher ASPs in Israel and the international markets — higher ASPs with no excise tax. And finally, in Canada, our vape portfolio has seen tremendous growth, and that line carries the strongest margin we have. Taken together, those elements created a perfect storm of favorable dynamics. As I said in the prepared remarks, we think the gross margin results across that trailing 12-month stretch give a clearer picture than this single quarter does.

Bill Kirk analyst
#18

Thanks. I'll make sure that gets shared.

Operator operator
#19

Thanks. The next person to ask a question is Derek Dley with TD Cowen. Your line is open now.

Derek Lessard analyst
#20

Morning, everyone. These are truly impressive results—nice work, Mike, to you and your group. Appreciate the detail you've shared so far. I suppose my question has two parts. First, did these numbers come in above what you had anticipated internally? And second, is there anything you could highlight that really worked in your favor during the quarter? I believe Anna touched on part of that, but I'd be curious to hear your perspective.

Mike Gorenstein executive
#21

Thanks. I appreciate that. Look, I'd say overall we're optimistic, though we always stay conservative, and all of us are very happy with these results. I think what you saw was things going well in just about every market and category. I can't really name one single item I'd single out. In Canada, we've discussed it over the past few quarters with Puffers launching and beginning to build momentum, and that has definitely been a major driver. I think that, on the whole, having additional supply has been really beneficial, simply in terms of being able to meet a lot of the demand we've said is out there but that we couldn't fill. When you consider yields along with the weather and the growing season, that was definitely a positive. Things are simply heading the right way across most markets, and a lot of the effort we've invested over the last few years is starting to pay off, and as we keep fine-tuning at GrowCo and with some of the manufacturing at Stayner and Israel, things are getting better.

Derek Lessard analyst
#22

Sure. On Canada specifically, I suppose there's been some discussion about a consumer under pressure up there and a shift toward products that offer more value. That doesn't appear to be happening, or at least you folks haven't encountered that issue, but any thoughts on what you're observing from the standpoint of the Canadian consumer would be useful.

Mike Gorenstein executive
#23

For us, it really comes down to delivering value — the value proposition is the key thing. To some, that could mean the value category, and for us, as long as we keep providing more value, I think there's still plenty of opportunity within our segments. I think you can also observe some switching that happens purely on cost from other categories — you might see somebody who was perhaps considering beer and, thinking about what's more cost-effective, may shift over to cannabis. We really haven't observed many problems when it comes to consumer resiliency, but I understand that it's more widespread out there.

Derek Lessard analyst
#24

Thanks, Mike, and congratulations once more.

Mike Gorenstein executive
#25

I appreciate that.

Operator operator
#26

Thanks. Next up, we have a question from Indigo Baylis at Canaccord Genuity. Please proceed.

Indigo Baylis analyst
#27

Good morning. This is unclear from Canaccord on the line. Nice work on the quarter. My questions are about the GrowCo integration, really. GrowCo seems to be progressing quite well. I wanted to ask whether you could comment on how that added supply is helping you pick up market share, and then on leveraging this facility as your next strategic area of focus. The second part of that is, I suppose, what you expect from the site once it's fully ramped, and how it could add to the top line and to gross margin down the road.

Mike Gorenstein executive
#28

Absolutely. Thank you. I believe it's progressing quite nicely. It's entirely online now. As we keep fine-tuning it over time, I think you'll see additional efficiency improvements—whether that involves the facility itself or just refinements, plus the genetic breeding program we've run for years. Each year, I think you get to see fresh genetics emerge, and there are many enhancements that have us genuinely excited. When you consider where efficiency opportunities lie, genetics is honestly difficult to quantify and present the way you can with constructing a facility versus genetic breeding, yet I still believe genetics is likely the area where the greatest efficiency gain will show up. I think GrowCo is performing exceptionally well. With that additional supply—since flower still makes up most of the global market—the gains we've achieved come from a combination of having more flower, I believe greater strength in pre-rolls, greater strength in vapes, and preserving the lead we hold in edibles. I think all of them contribute in some way. The facility expansion is really about adding more grow capacity to what we already had; it's fully integrated on the processing side, and then it was simply a matter of working out scheduling, being able to move the increased product through, and I think that's something we now have completely under control.

Indigo Baylis analyst
#29

Excellent. I appreciate it.

Operator operator
#30

Thanks. The next person to ask a question is Pablo Zuanic of Zuanic & Associates. Your line is open now.

Pablo Zuanic analyst
#31

Thanks, and good morning to all of you. Mike, could you go into more detail about your supply chain in Israel? I'm not sure whether you're able to discuss what share of what you sell comes from Cronos production in Israel and what portion is imported. I'm simply trying to get a sense of how much flexibility exists to increase domestic output if import restrictions come into play. In addition, whenever you report total Israel sales, is product purchased from third parties included in that figure—whether those parties are located in Israel or outside Israel serving that market? Thank you.

Mike Gorenstein executive
#32

Absolutely. We do have growing operations here domestically, it's true. We purchase from third parties as well — whether that's Israel or elsewhere — and we also buy from GrowCo up in Canada. All of that gets captured when you look at sales in Israel. It covers everything passing through our facility, and we sell it under our own brand. Packaging and manufacturing both happen at that site, on top of the growing itself. Let me just step back and say we genuinely don't believe the anti-dumping investigation has any merit. We've already been through one of these, and if you look at the outcomes, it's pretty clear: this isn't a market where we're saying, "Oh, we've got to dump excess product." We see it as a strong and important piece of our business. We've boosted supply with Israel in mind, we'll keep doing that, and we're confident we'll prevail once again.

Pablo Zuanic analyst
#33

Thanks. Now, just on the U.S. — in a recent podcast, I believe you said you have a plan mapped out for different scenarios, right? Sort of a matrix: if this occurs, you take this action; if that occurs, you do something different. Say we get rescheduling, but the state-by-state silo setup stays in place, with interstate commerce, no exports, no FDA federal oversight, and the states handling all the regulation — in that kind of scenario, would Cronos be interested in taking part and becoming more involved in the U.S., or not really, if nothing shifts on that front?

Mike Gorenstein executive
#34

If that's the premise behind your question, then you're envisioning the current setup staying frozen—where state-level medical markets exist and could in theory be accessed, but adult-use doesn't carry over, and we're assuming no interstate commerce. Setting aside for a moment whether Schedule III might create complications around interstate commerce, I think our approach would be to come in concentrating more on borderless products rather than on full-scale production sites. Even though we could assume things stay locked in this configuration indefinitely, I still find it difficult to believe that eventually you won't see interstate commerce and free trade, simply given what happens in every other industry and the fact that the dormant Commerce Clause is fairly robust. We'd be looking to enter with a range of products. When you hear us refer to borderless products, that's the flexibility it gives us. I still believe there are ways to come in with genetics, with our edibles, with our vapes, with pre-rolls, but without necessarily constructing really substantial grow infrastructure. Leaning more toward an IP focus rather than full production.

Mike Gorenstein executive
#35

My view is that this will broaden, because in the end I genuinely believe it will be extremely difficult to begin constructing infrastructure one state at a time when you will ultimately need to compete against something centralized that takes on far greater fixed costs and generates output on a national scale, much like what any CPG company does.

Pablo Zuanic analyst
#36

Alright, thank you. Just one more. Your stock's liquidity — and more broadly, that of Canadian LPs listed on the Nasdaq — has fallen considerably as time has gone on. There are those U.S. MSOs that are expected to uplist onto the NYSE or Nasdaq, and that's supposedly a major catalyst, correct? One could argue that here we have quite substantial Canadian licensed producers such as yourselves, already listed on the Nasdaq, and yet investor or stock liquidity remains thin, right? From where you sit, what accounts for that? Is it simply that there's far too much attention on the U.S. and that's the only thing investors want, so they overlook what's going on in the Canadian rec market and all that very large export potential Canadian LPs hold? What's your view on it? I'm just trying once more — I don't want to repeat the question — but why, when we have these Nasdaq-listed vehicles right now with all this growth, is the liquidity for the stock so low, generally? Thanks.

Mike Gorenstein executive
#37

That's a hard one to answer. For the market's size, there are probably a great many companies in it, and I'd say one difficulty is that at times the loudest firms and those with the most liquidity are simply making plenty of promises and have burned investors — this industry has become much more of a "show me" one now. I don't truly frame it as U.S. versus Canada. Every company is different, in my view. It's no longer simply that there are two categories of company in an LP or an MSO. I think you're increasingly seeing those dividing lines shift, and it isn't necessarily only Canada, right? You're looking at the rest of the world versus the U.S., and somewhere in both. Ultimately, my view is that people always ask us about capital deployment, and I think we've been handed a pretty good opportunity in terms of having a buyback so long as things remain the way they are. That's not something I really worry about. Using our stock as currency isn't necessary for us. Raising capital isn't necessary for us; we really just focus on what the market opportunity is. We still believe there's plenty of opportunity within the markets we have today, even with the situation in the U.S.

Pablo Zuanic analyst
#38

Okay, thanks.

Operator operator
#39

Thanks. That brings the Q&A portion and today's conference call to a close. We appreciate everyone joining us on today's conference. That wraps up our program. You're welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.